 |
|
Perspectives on the Relative Resurgence of Mumps in the United States
Stephen L. Cochi, MD;
Stephen R. Preblud, MD;
Walter A. Orenstein, MD
Am J Dis Child. 1988;142(5):499-507.
Abstract
| |
• Although the United States has enjoyed great success in the control of mumps since the licensure of live virus mumps vaccine in 1967, a relative resurgence of mumps during the 1986-1987 period has raised concerns about the long-term effectiveness of mumps vaccine. We reviewed mumps surveillance data, historical information on mumps vaccine distribution and recommendations for its use, survey data on levels of mumps immunization in US children during the 1973-1985 period, the effect of mumps immunization school laws on the reported incidence of mumps among states with and without such laws, and studies of mumps vaccine effectiveness. Following licensure, a decade elapsed before mumps vaccine was endorsed as a routine immunization of childhood, while immunization survey and vaccine distribution data reflected only gradual acceptance of the vaccine. However, mumps incidence declined during this period, resulting in a relatively underimmunized cohort of children born between 1967 and 1977 who grew up during a period when the risk of exposure to mumps was rapidly declining. The resurgence of mumps since 1986 has been characterized by a selective increase in incidence and a shift in the age group at highest risk to middle and high school students in those states lacking comprehensive mumps immunization school laws. Postlicensure field evaluations of mumps vaccine effectiveness have not demonstrated waning vaccine-induced immunity. The data indicate that the relative resurgence of mumps in the United States is chiefly due to a failure to vaccinate all susceptible persons, especially those who are now between 10 and 19 years old. Mumps immunization school laws offer an approach to deal with the problem of continuing susceptibility in school-age populations.
(AJDC 1988;142:499-507)
Author Affiliations
From the Division of Immunization, Center for Prevention Services, Centers for Disease Control, Atlanta.
Footnotes
Accepted for publication Jan 21, 1988.
Reprint requests to Technical Information Services, Center for Prevention Services, Centers for Disease Control, Atlanta, GA 30333.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Human Leukocyte Antigen and Cytokine Receptor Gene Polymorphisms Associated With Heterogeneous Immune Responses to Mumps Viral Vaccine
Ovsyannikova et al.
Pediatrics 2008;121:e1091-e1099.
ABSTRACT
| FULL TEXT
Effectiveness of Previous Mumps Vaccination During a Summer Camp Outbreak
Schaffzin et al.
Pediatrics 2007;120:e862-e868.
ABSTRACT
| FULL TEXT
Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity
Brisson and Edmunds
Med Decis Making 2003;23:76-82.
ABSTRACT
Evolution of Surveillance of Measles, Mumps, and Rubella in England and Wales: Providing the Platform for Evidence-based Vaccination Policy
Vyse et al.
Epidemiol Rev 2002;24:125-136.
FULL TEXT
Projected Cost-effectiveness of Pneumococcal Conjugate Vaccination of Healthy Infants and Young Children
Lieu et al.
JAMA 2000;283:1460-1468.
ABSTRACT
| FULL TEXT
Inadequate Immunizations: Identification Using Clinic Charts
Hymel et al.
CLIN PEDIATR 1993;32:156-160.
ABSTRACT
Mumps--United States, 1985-1988
JAMA 1989;261:1702-1708.
Progress Toward Achieving the National 1990 Objectives for Immunization
Arch Pediatr Adolesc Med 1988;142:1279-1280.
ABSTRACT
Progress Toward Achieving the National 1990 Objectives for Immunization
JAMA 1988;260:2629-2632.
|
